Cortex District Member Cofactor Genomics Lands Investments from Labcorp, Ascension Ventures

Cofactor Genomics, a St. Louis-based biotech company, has received new investments that it says will allow it to accelerate expansion of its OncoPrism immunotherapy-response diagnostic technology.

The company said Monday that it has received "strategic investments" from Labcorp Holdings (NYSE: LH), the Burlington, North Carolina-based lab services business, and Ascension Ventures, the venture capital arm of St. Louis-based nonprofit health system Ascension.

The amounts of the investments haven't been made public, Jarret Glasscock, Cofactor's president and chief technology officer, said in an email. The financing will support continued expansion of the company's predictive immunotherapy diagnostic portfolio, increased clinical evidence generation and health-system integration, and scaling of commercial and lab operations, officials said in a news release.